medic suppli devic
med-tech matchmak deal idea
messag slow start year med-tech activ pick
time dust settl transact announc make
busiest year databas go back yet despit activ large-cap
med-tech balanc sheet remain rel healthi today elev small-cap
valuat still potenti obstacl deal particularli high end growth
spectrum think like overal med-tech environ remain activ
spirit valentin day report play matchmak analyz
five hypothet pair believ could make sens strateg perspect
note transact mention strictli hypothet
knowledg strateg discuss current underway assign
probabl consumm detail accretion/dilut calcul
assumpt avail upon request
get year deal let look back last year busi one
med-tech overal four list compani acquir deal privat
compani domin total privat compani bought public med-tech
player eclips total prior two year combin set record
front go back least despit dearth public-for-publ transact
one matchmak deal come fruition scoop group
bolster spine divis meanwhil also report take-over target
cours year see although offici link rather
read full matchmak report deal
sniff anoth ent deal consist one
activ acquir large-cap med-tech past year one deal
work well compani thu far dec purchas entellu
medic expand syk ent presenc provid product breadth
scale justifi break sale forc dedic group within instrument
divis see logic next step ent buildout believ
would check mani box entellu fact higher gm superior
long-term growth potenti view strateg fit arguabl even
attract especi true consid fact post-entellu
infrastructur place make true bolt-on allow quickli
realiz cost synergi primari appeal transact would
gain access intersect differenti line steroid-elut bioresorb implant
xent recent announc develop novel balloon sinuplasti system
could potenti disrupt entellu core market add defens element well
abbott find diamond back rough larg sat sidelin
 play field digest st jude aler deal
time compani aggress paid debt reduc net leverag ratio
process recent convers investor that led question
whether abbott could seek anoth larg transact good
option avail make big splash front view think abbott
like tip toe back water smaller tuck-in deal one area compani
could look address vascular busi lag rest medic
devic divis past two year due on-going pressur de franchis
believ abbott lack exposur faster grow peripher vascular market also
put disadvantag acquir could allow abbott fill
peripher portfolio put even foot major competitor meanwhil
join abbott would give broad intern reach lack today without
surrend distributor margin current pay orbusneich
page analyst certif import disclosur
zimmer portfolio upgrad process get nerv repair sinc take
leadership zimmer biomet decemb ceo bryan hanson stress need
upgrad compani weight averag market growth rate wamgr
year later portfolio upgrad process yet get underway base busi
stabil howev believ could turn attent see
type asset zimmer consid evalu potenti deal
axogen line nerv repair product would complement zimmer exist trauma upper
extrem dental segment expand presenc hand specialist
plastic surgeon meanwhil zimmer could leverag leadership joint replac
facilit expans neuropath pain market meta-analysi
find total hip knee replac patient suffer complic
zimmer global presenc would provid foundat take current us-
busi intern much effici could
stryker final enter market highlight potenti take-over
candid matchmak report thesi addit compani
senza system could help revit neuromodul busi
time experienc thirteen straight quarter neg sale growth forward
today fastest grow four major player
lost mojo amid chang commerci leadership team challeng attract
retain sale rep rapid chang fortun illustr volatil
neuromodul segment believ remain attract market never
shi interest one day enter market doesnt
major presenc intervent pain space today potenti synergi
engin front like major player portfolio
core compet one area given troubl late effect
sale forc manag ceo kevin lobo said recent confer call know
run great offens could give anoth opportun demonstr
smith nephew find wright wright medic subject period
take-over discuss ever sinc bob palmisano join ceo yet whenev
thesi crop past view deal less like bull case
imagin due product overlap potenti acquir integr risk relat
tornier merger uncertain conserv legal liabil first
potenti impedi still true today latter two improv significantli
past year wright busi perform well time
sinc tornier deal believ time may final right transact come
togeth long view smith nephew best strateg fit wright given
limit extrem exposur need diversifi away slow growth recon busi
lack scale competitor new ceo namal nawana emphas
desir get aggress front rais snn wamgr expand
higher growth adjac potenti transact would accomplish goal better
tie-up wright view
financi time report friday close smith nephew talk buy
see articl state deal may final
smith nephew buy believ would like preclud snn consid
transact near-term
page analyst certif import disclosur
med-tech wave continu
slow start year med-tech activ pick back back half
time dust settl total transact excess
announc make busiest year databas go back
deal volum remain robust howev transact size significantli averag
up-front consider drop vs prior two year
exclud stj bcr mega-d result total deal valu came
run rate see figur part reflect shift toward earlier-
stage asset saw privat compani acquir public player eclips
total past two year combin set record front well see
meanwhil four us-list small-cap med-tech compani caught bid last year
one ktwo transact propos last year matchmak
other laborie/cgnt syk/ivti rel small deal valu
apiec final one mzor end result exist commerci
develop partnership didnt see activ suspect
slowdown small-cap partli function would-b buyer balk
high multipl ascrib mani attract asset space
dynam also encourag privat compani seek public exit total nine
med-tech ipo price last year sinc saw
figur med-tech target type
see view balanc sheet capac certainli
support strong environ figur show averag
debt/ebitda ratio across mid-to-larg compani includ analysi
stand today net basi flat year ago
sever compani made progress pay debt
lever one notabl except trend activ
 front track approach leverag propos btg deal close
page analyst certif import disclosur
believ mean boston may take breather near-term sever
manag team express desir deploy capit strateg includ
mazor deal remain rel quiet also
larg sit sidelin anyth quiet averag five
deal per year sinc yet continu enjoy ampl flexibl net
debt/ebitda ratio meanwhil although abbott ceo mile white comment
call doesnt see high prioriti right compani enter
year signific balanc sheet capac first time sinc
although small-cap multipl high elev valuat remain
potenti obstacl increas deal activ index small-cap med-tech name
trade averag multipl ntm sale today
end septemb remain well long-term averag high growth
name continu command out-siz premium rel rest group
effect price attract asset market potenti takeout
scenario view result think uptick public small-cap
overal deal size like return level may unrealist
forma announc deal yet close
methodolog report lay five deal believ make sens
strateg perspect note transact mention strictli
hypothet knowledg discuss current underway
assign probabl consumm also take stanc
specif fair valu target compani takeout scenario rather
assum rang base averag premium multipl paid past transact
small-cap deal appli premium target last close
price base averag premium paid compar transact
past decad larger deal assum multipl ltm ep
approxim rang similar transact sinc keep thing simpl also
assum transact close decemb base estim
current factset consensu forecast non-cov compani detail
accretion/dilut calcul assumpt avail upon request
page analyst certif import disclosur
consist one activ acquir large-cap med-tech
past year averag five deal per year sinc peer like
focus primarili privat asset hasnt shi
bid publicli trade compani close five transact alon
one work well compani thu far decemb
purchas entellu medic expand stryker presenc ear nose
throat ent market call ent previous instrument
divis lack overal product breadth justifi invest dedic sale forc
put disadvantag rel competitor like entellu
provid scale warrant invest strong exist sale team build
upon also give differenti product latera strong growth
prospect gross margin solidli corpor averag
see logic next step ent buildout intersect would check
mani box entellu fact higher gm vs
superior long-term growth potenti view strateg fit arguabl even
attract especi true consid fact post-entellu
infrastructur place make true bolt-on allow quickli
realiz cost synergi believ primari appeal transact
would gain access intersect differenti line steroid-elut
bioresorb implant xent recent announc develop novel balloon
sinuplasti system could potenti disrupt entellu core market add defens
element well
come difficult believ intersect growth acceler stori
defer debunk suppos inflect year intersect
launch new sinuva implant devolv seri disappoint
manag underestim logist challeng roll new physician-
administ drug specialti use buy-and-bil product procur system
prefer mani insur result confus forc compani rep spend
time triag sinuva reimburs claim rather seek new busi caus
sharp slowdown base propel/contour product line
page analyst certif import disclosur
intersect ad increment support resourc reliev burden
combin improv sinuva coverag major insur polici
place mount evid success payment buy-and-bil model set
compani potenti reacceler growth move
estim acquisit could neutral ep year
gener assum purchas price
premium friday close base averag premium paid compar
transact past ten year impli multipl sale
deal would add overal top line growth math meanwhil cost
synergi could help deliv long-term commit around oper
leverag intersect spend sale sg today number believ could
rapidli cut compani integr syk exist ent sale infrastructur
neutral ep year estim deal would add stryker
ep lift earn compound-annual-growth-rate process
abbott find diamond back rough
abbott larg sat sidelin play field digest
st jude aler deal time compani aggress paid debt
reduc net leverag ratio process recent
convers investor that led question whether abbott could seek
anoth larg transact ceo mile white threw cold water idea
call said compani capac deal
doesnt see high prioriti cours shouldnt taken gospel mr
white long success histori dealmak similarli dismiss
potenti st jude combin month transact announc
good option avail make big splash front view
think abbott like dip toe back water smaller tuck-in deal
one area abbott could look address vascular busi compani
medic devic segment overal perform except well past two year
vascular notabl laggard post back-to-back year flat declin sale
underli basi main culprit weak abbott coronari stent
franchis struggl face competit product launch demis
absorb program on-going price pressur
believ abbott lack exposur faster grow peripher vascular
market also put disadvantag rel competitor compani
solid bare metal stent offer peripher side led supera franchis
miss boat drug-coat balloon doesnt particip
atherectomi segment long thought deal spectranet would logic
way abbott close product gap philip swoop acquir spnc
abbott distract st jude integr februari
compani announc agreement secur exclus
world-wide distribut right srdx surveil drug-coat balloon exchang
up-front payment potenti mileston pivot trial compar
surveil medtron admir current underway potenti data readout
page analyst certif import disclosur
acquir cardiovascular system could allow abbott fill rest
peripher vascular portfolio put even foot major
competitor player peripher atherectomi market
diamondback system take coronari atherectomi share
recent year well strong presenc difficult treat knee segment
broad recognit physician solut choic heavili calcifi lesion
see csii competit posit peripher space highli defens juli
also announc agreement privately-held aerolas develop laser
atherectomi system manag believ could readi launch
figur peripher vascular devic duct map forma abt/csii
compani report guggenheim secur llc
meanwhil join abbott would give broad intern reach lack
today around time aerolas announc unveil
intern distribut deal orbusneich sell diamondback geographi outsid
 japan vascular sale come intern
market believ abbott could acceler ou roll-out
elimin need pay distributor econom orbu hasnt
disclos whether current agreement includ chang control provis think
like
estim acquisit could break-even abbott year
gener assum purchas price premium
friday close base averag premium compar transact
impli multipl sale estim deal would boost abbott
vascular growth rate next three year add
page analyst certif import disclosur
sinc take leadership zimmer biomet decemb ceo bryan hanson
stress need upgrad compani weight averag market growth rate
wamgr branch higher growth adjac year later
howev portfolio upgrad process yet get underway believ delay
due mostli manag desir stabil base busi prior ad
anoth layer complex qualiti remedi warsaw north
facil continu throughout suppli recov normal level
zimmer narrow under-perform rel broader hip knee market
suggest compani could turn attent strateg capit deploy
mr hanson suggest much call say target
attract us make financi strateg sens think provid good sharehold
return would certainli look target today
one factor remain potenti limit zimmer balanc sheet despit pay
debt past year compani net leverag ratio bare budg
today vs exit ebitda also declin despit lack
progress think zimmer actual closer meaning balanc sheet flexibl
may appear base busi stabil begin build momentum
model call free cash flow ramp alloc
cash primarili debt paydown today reduc net leverag exit
think zimmer could creat valu elong debt paydown
timelin begin process diversifi new market rais
ceil long-term growth trajectori
see axogen type asset zimmer consid evalu
potenti deal line nerv repair product would complement zimmer
exist trauma upper extrem dental segment expand presenc
hand specialist plastic surgeon meanwhil zimmer could leverag leadership
joint replac facilit entri neuropath pain market
zimmer global presenc would provid foundat take current us-onli
busi intern much effici could
signific pressur late sinc vs russel
due investor concern futur competit sustain
growth rate question increas risk potenti acquir see
uncertainti reflect share current level believ addit could
value-add zimmer even street forecast futur growth trajectori prove
estim acquisit could add zimmer ep
gener assum purchas price
premium friday close base averag premium paid
compar transact past ten year impli multipl
sale estim zimmer could financ transact size cash hand
exist credit facil without jeopard abil continu retir senior
note matur next year deal would add
compani overal top line growth rate math meanwhil
neutral ep year estim acquisit would add zimmer
ep lift earn compound-annual-growth-rate process
page analyst certif import disclosur
stryker final enter market
differ year make highlight potenti takeout
candid matchmak report thesi addit compani
senza system could help revit neuromodul busi
time experienc thirteen straight quarter neg sale growth
hand ride high captur spinal cord stimul market
first two year follow fda approv forward today medtron
deliv fastest world-wide growth four major competitor
market driven introduct next-gen intelli platform meanwhil nevro
seen growth slow share flatten amid chang commerci
leadership team challeng attract retain sale rep abbott face
issu result sharp deceler busi fact
three four major spinal cord stimul player experienc point swing
growth rate
compani report guggenheim secur estim
compani report guggenheim secur estim
rapid chang fortun illustr volatil neuromodul
segment believ remain attract market estim world-wide sale
grew cc revenu although
growth rate modestli respect believ
outlook market go forward remain strong particularli opioid epidem
encourag increas util non-pharmaceut solut manag
chronic pain pure play market meaning scale think make
compel target potenti acquir look enter space
hasnt shi ambit ceo kevin lobo note
compani analyst meet ive say last four year
neuromodul area interest compani doesnt
presenc intervent pain space today potenti synergi engin
front like major player portfolio compani
core compet one area given troubl late effect
page analyst certif import disclosur
